{"id":"W2554514455","doi":"10.1182/blood.v124.21.3990.3990","title":"First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; Saint John Regional Hospital; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Melphalan; Multiple myeloma; Maintenance therapy; Busulfan; Bortezomib; Minimal residual disease; Internal medicine; Regimen; Progressive disease; Plerixafor; Oncology; Autologous stem-cell transplantation; Surgery; Bone marrow; Urology; Transplantation; Chemotherapy; Hematopoietic stem cell transplantation; CXCR4","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002968095,0.0007133479,0.001462749,0.0001770952,0.001084831,0.001031034,0.0007175811,0.001215189,0.002460433],"category_scores_gemma":[0.001777031,0.0003220092,0.0007784579,0.0003616638,0.0007619743,0.0003579971,0.0003638201,0.001553606,0.0003751347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006367277,"about_ca_system_score_gemma":0.01314864,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2099485,"about_ca_topic_score_gemma":0.5760518,"domain_scores_codex":[0.9987904,0.0003491732,0.0000592548,0.0001783852,0.0003327634,0.0002899139],"domain_scores_gemma":[0.9982845,0.0002883064,0.0001408607,0.00008569672,0.0002853881,0.0009151259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4130633,0.0220504,0.1015691,0.002286104,0.004789057,0.003355338,0.001401079,0.003145864,0.05045324,0.002067691,0.1315831,0.2642356],"study_design_scores_gemma":[0.2799846,0.3221816,0.218466,0.0003158685,0.004295582,0.001973864,0.0004382415,0.002842201,0.0166906,0.001137226,0.1514312,0.0002430362],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9047969,0.009049149,0.001763884,0.01086404,0.0009139797,0.01185894,0.02400453,0.0001824318,0.03656613],"genre_scores_gemma":[0.9604408,0.002267423,0.003512124,0.007404429,0.0003580906,0.001514532,0.01083858,0.00008136746,0.01358261],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7900515,"threshold_uncertainty_score":0.4174529,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0489398456507827,"score_gpt":0.3201919338570257,"score_spread":0.271252088206243,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}